These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20139856

  • 1. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG.
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [Abstract] [Full Text] [Related]

  • 2. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
    Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
    [Abstract] [Full Text] [Related]

  • 3. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P.
    Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
    [Abstract] [Full Text] [Related]

  • 5. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone.
    Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, DiSanti W, Chun A, Keenan G, Mamun K.
    J Clin Gastroenterol; 2007 Aug; 41(7):677-81. PubMed ID: 17667052
    [Abstract] [Full Text] [Related]

  • 6. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P.
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
    Bermejo F, López San Román A, Algaba A, van Domselaar M, Carneros JA, Rivero M, Piqueras B, Valer MP.
    Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J.
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [Abstract] [Full Text] [Related]

  • 10. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders.
    Laharie D, Chanteloup E, Chabrun E, Subtil C, Kowo M, El Hanafi K, DE Lédinghen V.
    Aliment Pharmacol Ther; 2009 Jun 15; 29(12):1240-8. PubMed ID: 19416134
    [Abstract] [Full Text] [Related]

  • 11. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
    Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF.
    J Gastroenterol Hepatol; 2007 Feb 15; 22(2):268-74. PubMed ID: 17295882
    [Abstract] [Full Text] [Related]

  • 12. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 15; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 13. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA.
    J Clin Gastroenterol; 2010 Jan 15; 44(1):34-7. PubMed ID: 19417683
    [Abstract] [Full Text] [Related]

  • 14. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology.
    Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M.
    Minerva Gastroenterol Dietol; 2008 Sep 15; 54(3):239-42. PubMed ID: 18614972
    [Abstract] [Full Text] [Related]

  • 15. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G.
    Am J Gastroenterol; 2004 Jun 15; 99(6):1122-8. PubMed ID: 15180735
    [Abstract] [Full Text] [Related]

  • 16. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease.
    Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S, Knudsen T, Thorsgaard N, Munkholm P.
    Aliment Pharmacol Ther; 2012 Nov 15; 36(9):840-9. PubMed ID: 22971016
    [Abstract] [Full Text] [Related]

  • 17. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.
    Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, de'Angelis GL, Federici T.
    Dig Liver Dis; 2008 Jul 15; 40 Suppl 2():S260-4. PubMed ID: 18598998
    [Abstract] [Full Text] [Related]

  • 18. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C.
    Dan Med J; 2013 Apr 15; 60(4):B4616. PubMed ID: 23651723
    [Abstract] [Full Text] [Related]

  • 19. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease.
    Sazuka S, Katsuno T, Nakagawa T, Saito M, Saito K, Matsumura T, Arai M, Sato T, Yokosuka O.
    Eur J Clin Nutr; 2012 Nov 15; 66(11):1219-23. PubMed ID: 23010687
    [Abstract] [Full Text] [Related]

  • 20. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA.
    Aliment Pharmacol Ther; 2004 Oct 15; 20 Suppl 4():102-5. PubMed ID: 15352904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.